Starpharma Holdings Limited Net Income
| SPHRF Stock | USD 0.24 0.00 0.00% |
As of the 14th of February 2026, Starpharma Holdings has the Variance of 13.83, coefficient of variation of 1310.3, and Risk Adjusted Performance of 0.0694. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Starpharma Holdings, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for eleven technical drivers for Starpharma Holdings Limited, which can be compared to its competition. Please validate Starpharma Holdings mean deviation, total risk alpha, as well as the relationship between the Total Risk Alpha and kurtosis to decide if Starpharma Holdings is priced more or less accurately, providing market reflects its prevalent price of 0.24 per share. As Starpharma Holdings appears to be a penny stock we also recommend to double-check its information ratio numbers.
Starpharma Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Starpharma Holdings' valuation are provided below:Starpharma Holdings Limited does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Starpharma |
Starpharma Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Starpharma Holdings' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Starpharma Holdings.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Starpharma Holdings on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Starpharma Holdings Limited or generate 0.0% return on investment in Starpharma Holdings over 90 days. Starpharma Holdings is related to or competes with Bonus BioGroup, Celyad Oncology, Finch Therapeutics, and Microbix Biosystems. Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of... More
Starpharma Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Starpharma Holdings' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Starpharma Holdings Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0575 | |||
| Maximum Drawdown | 33.33 |
Starpharma Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Starpharma Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Starpharma Holdings' standard deviation. In reality, there are many statistical measures that can use Starpharma Holdings historical prices to predict the future Starpharma Holdings' volatility.| Risk Adjusted Performance | 0.0694 | |||
| Jensen Alpha | 0.2023 | |||
| Total Risk Alpha | (0) | |||
| Treynor Ratio | 0.2295 |
Starpharma Holdings February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0694 | |||
| Market Risk Adjusted Performance | 0.2395 | |||
| Mean Deviation | 1.13 | |||
| Coefficient Of Variation | 1310.3 | |||
| Standard Deviation | 3.72 | |||
| Variance | 13.83 | |||
| Information Ratio | 0.0575 | |||
| Jensen Alpha | 0.2023 | |||
| Total Risk Alpha | (0) | |||
| Treynor Ratio | 0.2295 | |||
| Maximum Drawdown | 33.33 | |||
| Skewness | 2.46 | |||
| Kurtosis | 19.01 |
Starpharma Holdings Backtested Returns
Starpharma Holdings appears to be out of control, given 3 months investment horizon. Starpharma Holdings owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0763, which indicates the firm had a 0.0763 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Starpharma Holdings Limited, which you can use to evaluate the volatility of the company. Please review Starpharma Holdings' Coefficient Of Variation of 1310.3, variance of 13.83, and Risk Adjusted Performance of 0.0694 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Starpharma Holdings holds a performance score of 6. The entity has a beta of 1.19, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Starpharma Holdings will likely underperform. Please check Starpharma Holdings' mean deviation, information ratio, as well as the relationship between the Information Ratio and kurtosis , to make a quick decision on whether Starpharma Holdings' existing price patterns will revert.
Auto-correlation | -0.91 |
Near perfect reversele predictability
Starpharma Holdings Limited has near perfect reversele predictability. Overlapping area represents the amount of predictability between Starpharma Holdings time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Starpharma Holdings price movement. The serial correlation of -0.91 indicates that approximately 91.0% of current Starpharma Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.91 | |
| Spearman Rank Test | -0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Starpharma Holdings Limited reported net income of (16.15 Million). This is 104.73% lower than that of the Healthcare sector and 123.06% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.83% higher than that of the company.
Starpharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Starpharma Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Starpharma Holdings could also be used in its relative valuation, which is a method of valuing Starpharma Holdings by comparing valuation metrics of similar companies.Starpharma Holdings is currently under evaluation in net income category among its peers.
Starpharma Fundamentals
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (3.13) % | |||
| Current Valuation | 123.62 M | |||
| Shares Outstanding | 408.92 M | |||
| Shares Owned By Insiders | 6.10 % | |||
| Shares Owned By Institutions | 44.65 % | |||
| Price To Earning | 46.82 X | |||
| Price To Book | 4.36 X | |||
| Price To Sales | 28.59 X | |||
| Revenue | 4.68 M | |||
| Gross Profit | (9.29 M) | |||
| EBITDA | (16.63 M) | |||
| Net Income | (16.15 M) | |||
| Cash And Equivalents | 49.92 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 4 M | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 5.93 X | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (13.16 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 50 | |||
| Beta | 0.85 | |||
| Market Capitalization | 161.85 M | |||
| Total Asset | 66.17 M | |||
| Retained Earnings | (154 M) | |||
| Working Capital | 40 M | |||
| Current Asset | 50 M | |||
| Current Liabilities | 10 M | |||
| Z Score | 21.2 | |||
| Net Asset | 66.17 M |
About Starpharma Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Starpharma Holdings Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Starpharma Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Starpharma Holdings Limited based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Starpharma OTC Stock
Starpharma Holdings financial ratios help investors to determine whether Starpharma OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Starpharma with respect to the benefits of owning Starpharma Holdings security.